Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07885501
Starting soon Observational

The Microbiome in Uveitis and Pediatric Inflammatory Diseases

NCT07885501 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2026-11
Last updated
2026-10-21

Condition(s) studied

Noninfectious Uveitis

Study summary

Chronic, noninfectious uveitis in children, associated with various systemic inflammatory diseases, carries a high risk of vision loss. Intestinal dysbiosis and the translocation of bacterial peptidoglycans (PG) that activate innate receptors recognizing PG could represent a common initiating mechanism, independent of the underlying disease. Studying these biological signatures in comparative cohorts could lead to a better understanding of the onset of uveitis and the development of targeted diagnostic and therapeutic strategies.

Eligibility

Sex
ALL
Min age
1 Day
Max age
17 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients under the age of 18 being treated at Robert-Debré Hospital * Patients being treated for noninfectious uveitis, or with pediatric inflammatory diseases without uveitis (connective tissue disorders, granulomatosis, juvenile idiopathic arthritis, pediatric vasculitides). * The child and his or her parents have no objection to participating in the study * Siblings of patients (family controls) or other healthy controls (children of hospital staff) Exclusion Criteria: \-

Primary outcome measure(s)

  • fecal peptidoglycans — Day 1
    the composition and relative abundance of fecal PG fragments in children with uveitis compared to healthy children.

Trial sites (1)

FacilityCityRegionStatus
Hôpital Robert Debré - APHP Paris France

More Assistance Publique - Hôpitaux de Paris trials in France

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases Recruiting
VExUS in Ards Patients and Association with AKI Recruiting
Periodontitis and Inflammation: Study on Biological Samples Recruiting
Kinematic Analysis of Latissimus Dorsi Transfer Results for Shoulder External Rotation Resuscitation Starting soon
Creation of a Biological Collection for Medical Research Purposes for Patients at the Reference Center for Rare Diseases of the Blood Vessels of the Brain and Eye at Lariboisière Hospital Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07885501 on ClinicalTrials.gov ↗ ← All trials in France